In 1972, Sharp et al. described a new autoimmune rheumatic disease that they called MCTD, characterized by overlapping features of SSc, SLE, PM/DM, high levels of anti-U1snRNP and low steroid requirements with good prognosis. MCTD was proposed as a distinct disease. However, soon after the original description, questions about the existence of such a syndrome as well as disputes over the features initially described began to surface. The conundrum of whether MCTD is a distinct disease entity remains controversial. We undertook a literature review, focusing on the articles reporting new data about MCTD published in the last decade, to determine whether any new observations help to answer the conundrum of MCTD. After reviewing recent data, we question whether the term MCTD is appropriately retained, preferring to use the term undifferentiated autoimmune rheumatic disease.
Introduction
Over 40 years ago, MCTD was envisaged as a condition characterized by high levels of antibodies to RNP, RP, swollen fingers, oesophageal dysfunction and the absence of lung and renal disease. These patients required low-dose steroids and the prognosis was good [1] . Within 10 years, major doubts about the original claims emerged. Nimelstein et al. [2] , in reviewing the original 25 cases, observed that some patients lacked high levels of anti-RNP, and 3 cases could not be identified. Furthermore lung and renal disease occurred, the steroid requirement could be high and the prognosis seemed closer to that of lupus patients. These and other data reviewed elsewhere [3, 4] led to major doubts about MCTD as originally defined and as a separate disease entity.
There have been four attempts to develop classification criteria and the conundrum of whether MCTD should be renamed continues. Here, we focus on the literature published about MCTD in the past decade. We sought to discover if any genuinely original insights have emerged to help unravel the MCTD mystery.
Methodology
Our literature review focused on articles in English published from 2005 to 2015. We identified 479 articles listing MCTD or anti-RNP as key words. After excluding case reports and articles focusing on UCTD, $100 articles remained, which formed the basis of this review. [7] and Kahn and Appeboom's [8] . Previous literature concluded that those of Alarcó n-Segovia and Villareal had the highest sensitivity and specificity, while Sharp's criteria had a lower specificity [9, 10] . One recent study [11] evaluated 161 MCTD patients at diagnosis and after a mean follow-up of 7.9 years, observing their evolution. Kasukawa et al.'s criteria were more sensitive (sensitivity 75%) compared with Alarcó n-Segovia and Villareal's (73%) or Sharp's (42%) criteria. The percentage of patients at final follow-up who satisfied one or more of the three classification criteria was lower compared with the time at diagnosis (Kasukawa et al.: 53% vs 75%; Alarcó n and Villareal: 44% vs 73%; Sharp: 32% vs 42%). Even using Kasukawa et al.'s criteria, >40% were no longer diagnosable as having MCTD. Of the remainder, 17.3% evolved into SSc, 9.1% into SLE, 2.5% into RA and 11.5% were reclassified as UCTD. The percentage of patients evolving into other autoimmune rheumatic diseases was lower in patients with disease durations of 05 years than in those >5 years. Using multiple variable regression, a significant association was found between anti-dsDNA at the first visit and evolution into SLE in those initially diagnosed with MCTD by Kasukawa et al.'s criteria [odds ratio (OR) 1.3; P = 0.012] and Alarcó n-Segovia and Villareal's (OR 1.4; P = 0.001). In patients with a first diagnosis of MCTD (Kasukawa et al.'s criteria), sclerodactyly (OR 1.2; P = 0.034) and oesophageal hypomotility or dilation (OR 1.4; P = 0.001) were associated with evolution into SSc.
Diagnostic criteria and disease evolution
Another study [12] reported that the point prevalence showed no statistical difference between the three criteria sets (Sharp, Alarcó n-Segovia and Villareal or Kasukawa et al.), indicating that they may be comparable [12] . The point prevalence of MCTD in living adults in Norway was 3.8/100 000, while the incidence of adultonset MCTD in Norway from 1996 to 2005 was 2.1/million/year.
A study [13] involving 280 MCTD patients reported different disease evolution observations. During follow-up, MCTD patients developed new symptoms, but did not show progression to other autoimmune rheumatic diseases. This finding contrasted markedly with earlier studies, which demonstrated that most patients with anti-U1RNP developed into classified autoimmune rheumatic diseases within 5 years of presentation. In these studies, Sharp's criteria were often used, which may be less specific than other criteria [14, 15] . In other reports, the classification criteria used for diagnosis were not confirmed [16] , which might have influenced the evolution rate.
Clinical features

Pulmonary hypertension
Pulmonary hypertension is a major clinical feature in MCTD, with a prevalence of 1050%. There are three recent prevalence studies. In one, pulmonary hypertension occurred at a frequency of 3.4% [17] . In the others, the prevalence of pulmonary arterial hypertension ranged from 14 to 17.9% in MCTD [13, 18] . Pulmonary hypertension associated with autoimmune rheumatic diseases is classified into five subgroups: group 1, pulmonary arterial hypertension (PAH); group 2, pulmonary hypertension due to left heart disease; group 3, pulmonary hypertension due to lung disease or hypoxia; group 4, chronic thromboembolic pulmonary hypertension and group 5, PH with unclear or multifactorial mechanisms [19] .
Thus PAH is just one subgroup in pulmonary hypertension. The 3.4% prevalence of pulmonary hypertension in the nationwide Norwegian multicentre cohort of 147 adult MCTD patients included isolated PAH and pulmonary hypertension due to interstitial lung disease (ILD) [17] . The lower than anticipated pulmonary hypertension prevalence was possibly explained by the selection of the study population. While previous studies usually assessed pulmonary hypertension in MCTD referred to tertiary centres, this study screened unselected MCTD patients throughout Norway, perhaps leading to a lower prevalence. Different studies have used different cut-offs on echocardiograms to screen for pulmonary hypertension before subjecting the patients to right heart catheterization. One used pulmonary artery systolic pressure of >40 mmHg as a cut-off [17] , while two others used right ventricular systolic pressure of 25 mmHg for screening [13, 18] . Pulmonary artery systolic pressure is considered equal to right ventricular systolic pressure in the absence of pulmonary outflow tract obstruction. This discrepancy might significantly affect the ascertainment rate for pulmonary hypertension.
Anti-U1RNP, anti-endothelial cell antibody (AECA), aCL and IgG anti-b 2 -glycoprotein I (anti-b 2 -GPI) might be associated with the development of PAH, suggested by higher levels of these antibodies in MCTD patients with PAH compared with those without. AECA was also associated with high serum thrombomodulin and von Willebrand factor antigens, indicating endothelial cell activation and damage [13, 18, 20] . Furthermore, anti-U1RNP might have a direct pathogenic role. Considering aPL, previous studies showed that aCL was not associated with thromboembolism in MCTD, and most aCL in MCTD sera is b 2 -GPI independent, which may explain the absence of associated clotting events [21, 22] . However, MCTD-PAH patients tended to have higher levels of aPL [13, 20] , suggesting its potential role in PAH. PAH in MCTD was noted to be more commonly associated with RP with abnormal nailfold capillaroscopy [23] .
In MCTD, diastolic function of the left ventricle was worse compared with a control group. For right ventricular function, there was global failure of right ventricle function in cases of MCTD complicated with PAH, while right ventricle function in those without PAH was not different from the controls [24] .
The pathophysiology of PAH in MCTD is similar to other autoimmune rheumatic diseases, especially SSc, but ILD was not significantly related to PAH in MCTD [25, 26] . Among autoimmune rheumatic diseases with associated PAH, 1 year survival and discharge from the hospital were lower in MCTD with PAH when compared with SLE, SSc and RA with PAH [27] . One recent review recommended that all patients with SSc, CREST (calcinosis, RP, oesophageal dysmotility, sclerodactyly, and telangiectasia) syndrome or MCTD should undergo annual screening with echocardiography for PAH, although right heart catheterization is the standard for definitive diagnosis. Cardiac MRI is complementary for diagnosing PAH [28] .
ILD
Two studies involving >100 MCTD patients showed that 47.1 and 52% had evidence of ILD [13, 29] . Another study evaluated ILD and oesophageal dysfunction and reported high-resolution CT abnormalities in up to 78% among 50 MCTD patients [30] . Nineteen per cent had severe lung fibrosis, and these patients had lower functional status. The mortality was significantly worse in severe lung fibrosis. These patients had shorter mean disease duration at study inclusion than patients with minor or moderate fibrosis, indicating a more rapidly progressive disease [29] .
Concerning ILD in MCTD, the most frequent histology is non-specific interstitial pneumonia, followed by usual interstitial pneumonia and lymphocytic interstitial pneumonia [28] . Anti-U1RNP antibodies may contribute to disease manifestations, as they induce pulmonary injury in murine models [31, 32] . A correlation was found between diffusing capacity for carbon monoxide and ILD, but not between total lung capacity and ILD [30] . This is probably because reduced diffusing capacity for carbon monoxide is the most sensitive test for predicting ILD. Oesophageal abnormalities may also be related to ILD. In MCTD, three different subphenotypes can be seen: subgroup 1, AECA and aPL associated with PAH, RP, livedo reticularis and vascular thrombosis; subgroup 2, presence of ILD, oesophageal dysmotility and myositis and subgroup 3, higher prevalence of anti-CCP antibodies and erosive arthritis.
In subgroup 2, the incidence of ILD was 98.7%, significantly higher than in subgroups 1 and 3 (P < 0.001). Nailfold capillaroscopy might help to differentiate the subgroups, as an abnormal scleroderma-like capillary pattern was found most commonly in the first subgroup (68.7% vs 26.5% and 33.3% in the other two subgroups). This SSc capillary pattern also correlated with aCL, AECA (P < 0.0001) and PAH (P < 0.05). The worst overall survival probability belonged to subgroup 1, where 11 of 17 patients died, 8 from PAH [33] .
Oesophageal involvement
Sixty-four per cent of MCTD patients had severe oesophageal dysfunction and 50% of patients had distal abnormal acid reflux. However, there was no statistically significant relation between oesophageal dysfunction and acid reflux. ILD was significantly higher among patients with oesophageal dilatation (92% vs 45%; P < 0.01) and severe oesophageal dysfunction (90% vs 35%; P < 0.001). No statistically significant differences in the frequencies of ILD between patients with normal or abnormal acid reflux were found [30] , that is, there was a correlation between severe oesophageal dysfunction and lung damage in the absence of acid reflux. Thus ILD may be associated with food reflux instead of acid reflux in MCTD. This observation was reminiscent of another study demonstrating abnormal lung function tests and significant delay in the clearance of the nucleotide on scintigraphy [34] .
Musculoskeletal involvement
Arthritis in MCTD has a possible association with RF and anti-CCP. Whereas RF was positive in 30100% of MCTD patients, anti-CCP was found in only 9%. Anti-U1RNP may be a predictor of more aggressive erosive arthritis [22] . Recent observations [35] included significantly higher levels of serum IgM-, IgG-and IgA-RF in MCTD patients when compared with controls (P < 0.05). The frequency of IgM-RF in MCTD patients was 48 vs 77% in RA. A recent review [36] reported 7595% of MCTD patients had arthritis. Around 50% of patients with frank arthritis have erosive arthritis. HLA-DR4 is associated with polyarthritis in MCTD.
There have been no major new observations of myositis in MCTD. Up to two-thirds of MCTD patients have overt myositis ranging from mild to severe [22] . When myositis patients with anti-RNP antibodies were compared with those without, the former group responded better to corticosteroids. Histologically, myositis in MCTD is indistinguishable from DM. Immunoglobulin deposits were found in muscles and it is an immune complexdriven disease [25, 37, 38] .
Cardiovascular involvement
The prevalence of cardiac involvement varies from 13 to 65% [39] . Pericarditis was the most common cardiac diagnosis, with prevalences of 30 and 43% in two prospective studies. Non-invasive cardiac tests detected subclinical cardiac abnormalities in 638% of patients. Diastolic dysfunction and accelerated atherosclerosis were well documented in a casecontrol study [24] . Two older and one recent prospective study revealed an overall mortality of 10.4% over the ensuing 1315 years. A total of 2.1% of patients died of direct cardiac causes [13, 40, 41] .
Endothelium-dependent vasodilation, assessed by flow-mediated dilation, was significantly impaired in MCTD (Alarcó n-Segovia and Villareal's criteria) vs controls [42] . The percentage of flow-mediated dilation was even lower in MCTD with cardiovascular diseases than in those without. The percentage of nitrate-mediated dilation did not differ between MCTD vs controls and MCTD patients with cardiovascular diseases vs those without. The mean carotid intima-media thickness was higher in MCTD patients than in controls.
Renal involvement
The original MCTD description stressed the paucity of renal involvement [1], but a later review showed that it occurred with a frequency of between 5 and 36% [43] . In one review [44] , 12 of 30 MCTD patients (40%) had renal involvement. The majority had membranous GN, followed by mesangial GN. Some patients had proliferative GN and a few had a scleroderma pattern [45] . Patients with renal disease have more systemic manifestations than those without. A total of 72% of nephropathy patients experienced resolution or improvement with steroids. Electron microscopy revealed immune complex deposition in the glomeruli [36, 44] . In MCTD patients, anti-U1snRNP seemed to have no correlation with nephropathy [44] . But in a study of a murine model [46] , immunization of mice with RNP antigen induced anti-RNP and MCTD clinical manifestations, typically ILD but not renal disease. In contrast, for mice deficient in Toll-like receptor 3 (TLR3), RNP antigen exposure induced SLElike GN. Exposure to RNP antigen in an appropriate context may induce autoimmunity and MCTD features, while changes in innate immunity or TLR signalling with the same trigger may lead to the development of SLE-like nephritis.
RP and capillaroscopy
Nailfold capillaroscopy findings are usually classified as normal, non-specific or scleroderma-like. The prevalence of RP observed in scleroderma and MCTD is generally 590% in most studies. There are two different types of scleroderma pattern: slow, with irregularly enlarged or giant loops with no or minimal capillary loss; and active, with definite capillary loss and neoformation of capillaries.
MCTD patients often demonstrate a slow scleroderma pattern. RP tends to be less severe in MCTD than in scleroderma, with fewer digital ulcers or loss of digits [47] .
In a recent prospective study enrolling >3000 patients with primary RP, initially none of the patients with primary RP had symptoms or signs of autoimmune rheumatic diseases and all had normal nailfold capillaries. After a mean of 4.8 years, 1660 (54.8%) patients still had primary RP, but 246 (8.1%) had suspected secondary RP and 1123 (37.1%) developed autoimmune rheumatic diseases (363 UCTD, 263 SSc, 143 SLE, 24 MCTD). Suspected secondary RP meant patients had no clinical signs of autoimmune rheumatic disease but had serological findings or abnormal nailfold capillaroscopy. A scleroderma pattern in capillaroscopy was significantly associated with development of SSc, dermatomyositis, overlap syndrome with signs of SSc and MCTD. The scleroderma pattern had a better negative than positive predictive value for possible development of an autoimmune rheumatic disease. Among the 24 patients who developed MCTD, half had normal capillaries and the other half had non-specific or scleroderma-type capillary changes. The scleroderma pattern was present in 9/24 (37%) patients with MCTD [48] . Another study involving >1000 patients with RP reported similar findings and noted that scleroderma-type capillary changes with RP was indicative of the development of an autoimmune rheumatic disease, despite the absence of other disease symptoms [49] .
In a Hungarian study [13] , the number of MCTD patients with the scleroderma pattern on capillaroscopy increased over time. The typical scleroderma pattern at the time of diagnosis of MCTD (Alarcó n-Segovia and Villareal's criteria) was found in 31.4%. During a mean 13.1 years of follow-up, there was a modest progression to 40.3%. More deceased MCTD patients had a scleroderma pattern compared with those MCTD patients who survived (38.3% of 258 living patients vs 63.3% of 22 deceased; P < 0.02). Another nailfold capillaroscopy study [50] performed on 63 MCTD patients (Kasukawa et al.'s criteria) noted that a scleroderma pattern was observed in 65% patients at entry and in 71.5% patients at a previous capillaroscopy before inclusion. Apparently capillaroscopy changed with treatment, as a reduced capillary density was more frequently observed in patients taking immunosuppressants than those without medication (66.7 vs 33.3%; P = 0.001). Nailfold capillary changes in MCTD seem to be a dynamic process.
MCTD demonstrates nailfold capillary abnormalities more reminiscent of SSc than SLE. But branched bushy capillary formations are believed by some to be characteristic of MCTD [25] . Despite the high frequency of RP in SLE in one study [51] , only 2% of SLE patients had an scleroderma pattern compared with 54% of MCTD patients. A relationship between anti-U1RNP and RP was reported. Anti-U1RNP may contribute directly to the vasculopathy. For a summary of the new findings regarding clinical features in the past 10 years, please refer to supplementary Table S1 , available at Rheumatology Online.
Serology and immunology
U1-snRNP is composed of U1-RNA, seven common core Sm proteins and three U1-specific proteins (U1-70K, U1-A and U1-C) [25] . The components of the spliceosome complex that anti-U1snRNP recognizes include the U1-RNA and the U1-specific polypeptides 70 kDa A and C in a study using Kasukawa et al.'s criteria. Anti-U1-70K were found in 7590% of MCTD patients (Sharp's criteria) and were the most commonly detected component. They were only found in 2050% of SLE patients who were positive for anti-RNP. Antibodies against the RNA component of U1-snRNP were found in 38% of anti-RNP-positive patient sera [21, 37, 52] .
Most MCTD patients have high titre anti-U1snRNP [25] , but anti-U1snRNP is not exclusive to MCTD. In a study of 161 MCTD patients, between 20 and 40% of SLE patients, 2 and 14% with SSc, and 6 and 9% with myositis were positive for anti-U1snRNP. Patients with RA usually lacked anti-U1snRNP antibodies [11] . IgM anti-U1snRNP titres were significantly higher in SLE patients than either MCTD patients (Alarcó n-Segovia and Villareal's criteria) or healthy controls (P 4 0.05). IgG anti-U1snRNP was significantly higher in SLE and MCTD populations than in the healthy group, but IgG reactivity was similar in both autoimmune rheumatic diseases. Combining IgM anti-U1C and anti-U1A, it was possible to classify SLE and MCTD patients with an accuracy of 71.3%, which was rather unsatisfactory [53] . Lower titre anti-U1RNP was found in SLE and was usually of the IgM isotype associated with antiSm [22] . Another review [25] also reported MCTD patients were less likely than SLE patients to retain IgM U1-snRNP antibodies, and claimed that long-standing high titre IgG U1-snRNP is typical for MCTD, conveying high specificity. This observation differs from the finding in the study of Mesa et al. [53] .
MCTD also differs from SLE and RA in response to another spliceosome-associated protein, the heterogeneous nuclear RNP. A recent study claimed that antibodies to Sm-D, which are present in the U1-snRNP and positive in 10% of white SLE patients, are largely specific for SLE. Patients who fulfil MCTD criteria rarely have antibodies to Sm [25] . Another cross-sectional comparative analysis of immunological markers in sera from 51 SLE patients, 10 MCTD patients and 59 controls reported different observations. Levels of anti-SmBB 0 or anti-SmD were similar in SLE and MCTD sera, although antibodies to SmD were more frequent in SLE. Also, since sera from MCTD had higher levels of anti-U1-70K than sera from SLE patients, high anti-U1-70K were useful for diagnosing MCTD [54] . Notably, 94% of MCTD patients vs 20% of SLE patients had sera with antibodies against U1-A protein [37] .
Anti-U1snRNP seemed to be a robust marker of MCTD onset. Its emergence preceded the onset of clinical manifestations [55] . Individual U1-RNP antibodies have been evaluated as markers of disease activity, measured by activity scales derived from lupus. Anti-U1-RNA titres correlated with activity, unlike anti-U1-70K titres [21] . During remission, antibodies to U1-70K, U1-A and U1-C decreased, suggesting a correlation between the autoantibodies and disease activity [37] . A control study that assessed B cell subsets in 46 MCTD patients (Alarcó nSegovia and Villareal's criteria) vs 20 healthy individuals showed that anti-U1RNP levels decreased after treatment (P < 0.0467) [56] .
Antigen modification is important in the pathogenesis of MCTD. One study of alterations in post-translational modifications (PTMs) on a U1snRNP 68 kDa subunit in four MCTD, four SLE, four RA patients and three healthy donors showed that MCTD and SLE patients were characterized by an increase of low phosphorylated U1-68K. PTMs on autoantigens were involved in the production of antibodies, as altered self-proteins created novel epitopes to which the immune system has not been tolerized [57] . The 70 kDa polypeptide of U1-RNP is susceptible to multiple forms of antigen modification, including PTM and caspase cleavage during apoptosis or oxidative cleavage in response to stress. Apoptotically modified 70 kDa polypeptide is antigenically distinct from intact 70 kDa polypeptide and may have clinical implications in breaking immune tolerance. Autoantibodies reactive with apoptotic 70 kDa polypeptide are superior markers to those against intact 70 kDa polypeptide for MCTD [21, 55] . In 53 MCTD patients, 29 (54%) preferentially recognized the apoptotic form of 70 kDa polypeptide compared with intact 70 kDa polypeptide [31] . The appearance of autoantibodies to U1-snRNP components follows a characteristic order. Antibodies to U1-70K and Sm-B/BV generally appear early. Anti-U1A and U1C and Sm-D are detected later. U1-70K is a major early immunogen. This, together with the fact that U1-70K is modified during apoptosis, suggests apoptotic modifications on U1-70K protein might be important for triggering immune response to U1snRNP [58] .
A cohort study evaluated 15 peptides in 68 SLE and 29 MCTD patients and 26 healthy individuals. U1-70K was the best at predicting which samples were in the SLE group from healthy samples and the second best at separating MCTD from healthy samples (P = 0.0001). Two other peptides from U1A protein were the best predictors of SLE vs MCTD (P = 0.167 and P = 0.206). Although they are not capable of definitively segregating SLE from MCTD, U1A may be the most likely protein that can distinguish the two diseases [59] .
There are two proposed mechanisms of the pathogenic role by anti-U1RNP. Anti-U1RNP can bind to endothelial cells and cause endothelial cell activation and damage leading to vascular disease pathogenesis, RP, puffy hands, sclerodactyly, pulmonary hypertension, possibly ILD and oesophageal dysmotility. They can also form immune complexes that might activate complement and induce myositis, (non-erosive) arthritis and perhaps ILD. The pathogenesis of erosive arthritis is unclear [22] .
A recent study reported that the proportion of transitional B cells, naive B cells and double-negative B lymphocytes was higher in MCTD patients (Alarcó nSegovia and Villareal's criteria) than in controls. The memory B cell population had a close correlation with disease activity measured by the systemic lupus activity measure. The number of plasma cells was also increased and there was an association between their number and anti-U1RNP levels. CYC, MTX and corticosteroid treatment decreased the number of double-negative and CD27 high B cells [56] . In a cross-sectional study involving 21 MCTD patients (Alarcó n-Segovia and Villareal's criteria), CD4 + CD25
high Tregs decreased with increasing levels of disease activity, although the correlation was not significant [60] . In another study of Treg cells involving 48 MCTD patients (Alarcó nSegovia and Villareal's criteria), the percentage and absolute number of CD4 + CD25 high Treg cells were lower in the MCTD patients than in controls (P < 0.04) and were further decreased in active MCTD and lower than in the inactive stage (P < 0.01). There was an increase in the percentage and absolute number of CD4 + IL-10 + Tregs in MCTD patients compared with healthy controls (P < 0.02). The percentage of CD4 + IL-10 + Tregs was higher during active disease than during remission (P < 0.005). The role of these cells in immunoregulation and inflammation is reviewed elsewhere [61] . Immune mechanisms that contribute to U1-snRNP immunogenicity include epitope spreading through B and T cell interactions and apoptosis-induced modifications. The spread of immunogenicity can occur within a single antigen to multiple epitopes on the same protein (intramolecular spreading) or to other epitopes within a greater macromolecular complex (intermolecular epitope spreading) [37] .
Genetics
Novel genetic associations within the MHC on chromosome 6 and select regions on chromosome 3 have been claimed for MCTD. The frequency of HLA-DR4 was increased in MCTD compared with healthy controls in worldwide population-based studies. In MCTD patients, no association was found with MHC haplotypes associated with SLE (HLA-DR3) or scleroderma (HLA-DR5) [55] . A significant association of U1RNP disease with HLA-DR4 and DR154-61 was noted, which was different from SLE or SSc [22] . Thus HLA evidence seems to favour MCTD being distinct from other autoimmune rheumatic diseases, and as a disease that is T cell dependent, given the HLA class II association. In contrast, other evidence implied HLA-DR4 seemed primarily to be related to U1-RNP antibody formation rather than disease expression. Patients with or without MCTD did not differ with respect to DR4 frequency. In these studies, some allotyped MCTD patients used SLE patients as controls, while others used healthy individuals. In certain studies, the MCTD patients exhibited a heterogeneous clinical picture with a few fulfilling the classification criteria for SLE or SSc. The classification criteria for recruiting MCTD patients also varied, with Sharp's and Alarcó n-Segovia and Villareal's criteria being used in different studies. Thus the claims made about the association of MCTD with HLA-DR4 remain confused [25] . Supplementary Table S2 , available at Rheumatology Online, summarizes the immunology and genetic findings in last decade.
Treatment
In the past decade there has been a lack of randomized trials. Management relies on extrapolation of guidelines for equivalent manifestations in SLE, SSc and RA. Immunosuppressive therapy and steroids remain the therapeutic mainstay for MCTD. A retrospective study of 161 patients with MCTD showed that 58% required aggressive immunosuppression and only 3% achieved disease control using symptomatic therapies [11] .
The use of anti-TNF-a in MCTD with refractory erosive arthritis was assessed in a prospective study of 280 patients. A total of 44 (17.5%) patients were diagnosed with erosive arthritis, and all except 2 were treated with MTX plus anti-TNF-a [13] . No adverse effects were reported. However, the experience with its use is limited and there are case reports that anti-TNF-a was associated with development of an SLE-like syndrome [62] .
The treatment of PAH associated with MCTD is complex. General measures (oxygen supply, diuretics, etc.) are usually insufficient and invariably more aggressive treatment with prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors is needed to improve pulmonary functional status [13] .
Surgical options are the alternative for those patients who continue to progress despite aggressive therapy. They include procedures like atrial septostomy and lung transplantation [26] .
Prognosis
The initial notion of MCTD being a benign disease was abandoned after many studies showing that most patients did not have favourable outcomes. Lundberg [43] reported that one-third of patients with MCTD had a benign course, one-third had an aggressive course and one-third improved with immunosuppressive therapy but required it for several years. However, the small number of longterm outcome studies limits our knowledge of morbidity and mortality in MCTD patients.
The principal causes of morbidity in the first years of MCTD were RP and oesophageal hypomotility. Sclerodactyly, diffuse sclerosis, PAH and nervous system disease are major causes of morbidity in longterm MCTD patients [43] . In a recent study, 12 of the 147 (8.2%) patients died after being followed up for a mean of 5.6 years. Three of the five patients with pulmonary hypertension died from right ventricular failure. In the other nine deceased patients, the causes of death were ILD (n = 2), coronary heart disease (n = 2), cancer (n = 4) and unknown (n = 1) [17] .
A prospective study of 280 patients found a survival rate of 98% at 5 years, 96% at 10 years and 88% at 15 years [13] . Twenty-two (7.8%) patients died. In 12 of 22 patients, the cause of death was directly related to MCTD manifestations. Ten patients died as a result of complications from MCTD.
The presence of cardiovascular events, oesophageal hypomotility, serositis, secondary APS and malignancy was significantly higher in the deceased patients. Also, the presence of aCL, anti-b 2 -GPI and AECA increased the risk of mortality [13] .
Conclusion
In supplementary Table S3 , available at Rheumatology Online, a comparison is shown of the original features that distinguished MCTD and the features currently claimed to constitute the condition. It shows that a major evolution in the concept has occurred. Some evidence implying that MCTD does exist as an entity has emerged from genetic studies, but the genetic association is actually not very consolidated. There are data showing that components of U1-snRNP are important for triggering immune responses and that anti-RNP has a central pathogenic role and may contribute to disease manifestations.
Nevertheless, there is no evidence that >40% of patients given a diagnosis of SLE, RA or SS change their clinical features to become recognized as another autoimmune rheumatic disease analogous to MCTD. We postulate that different forms of antigen modification and epitope spreading, together with B and T cell interactions, may have implications in disease evolution to other autoimmune rheumatic diseases. Thus we continue to question whether the term MCTD is appropriately retained, preferring to use the term undifferentiated autoimmune rheumatic disease.
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